세계의 악성중피종 시장

Global Malignant Mesothelioma Market to Reach US$975.2 Million by 2030

The global market for Malignant Mesothelioma estimated at US$681.2 Million in the year 2024, is expected to reach US$975.2 Million by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Premetrexed & Combination Drugs, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$518.6 Million by the end of the analysis period. Growth in the Cisplatin & Combination Drugs segment is estimated at 6.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$188.4 Million While China is Forecast to Grow at 5.7% CAGR

The Malignant Mesothelioma market in the U.S. is estimated at US$188.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$150.5 Million by the year 2030 trailing a CAGR of 5.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.0% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Malignant Mesothelioma Market - Key Trends & Drivers Summarized

What Is Malignant Mesothelioma and Why Is It Such a Serious Health Concern?

Malignant mesothelioma is a rare and aggressive form of cancer that primarily affects the lining of the lungs, abdomen, or heart, caused by asbestos exposure. Due to its long latency period—often several decades after exposure—mesothelioma is typically diagnosed at an advanced stage, making it a particularly difficult disease to treat. The poor prognosis associated with malignant mesothelioma, along with its limited treatment options, has made it a critical area of focus for researchers and healthcare providers. The link between occupational asbestos exposure and the development of mesothelioma has also spurred regulatory efforts to reduce exposure risks, but the disease remains a major health concern, especially for those working in industries like construction and shipbuilding.

How Are Advances in Treatment Improving Outcomes for Mesothelioma Patients?

Advancements in the treatment of malignant mesothelioma are providing new hope for patients facing this challenging diagnosis. Traditional treatment options, such as surgery, chemotherapy, and radiation therapy, have been complemented by emerging therapies that target the disease more precisely. Immunotherapy, which harnesses the body’s immune system to attack cancer cells, has shown promising results in extending survival rates for some mesothelioma patients. Additionally, targeted therapies that inhibit specific molecular pathways involved in cancer growth are under investigation, offering potential for more personalized treatment approaches. Clinical trials exploring the combination of these innovative treatments are a key focus of ongoing research, seeking to improve outcomes for patients who historically have had limited treatment options.

What Challenges Do Patients and Healthcare Providers Face in Managing Malignant Mesothelioma?

The management of malignant mesothelioma poses significant challenges, starting with the difficulty of early detection. Symptoms of mesothelioma, such as shortness of breath and chest pain, are often nonspecific and can be mistaken for other conditions, leading to delayed diagnoses. Moreover, the advanced stage at which the disease is typically detected limits treatment options and contributes to poor survival rates. Another challenge lies in the availability of specialized care, as treating mesothelioma requires a multidisciplinary approach involving oncologists, thoracic surgeons, and radiation specialists. Access to experimental therapies and clinical trials is also limited for many patients, especially those in underserved regions. Additionally, the high costs of treatment further complicate the management of this aggressive disease.

Growth in the Malignant Mesothelioma Market Is Driven by Several Factors

The growth in the malignant mesothelioma market is driven by several factors, including advancements in immunotherapy and targeted treatments, increasing research funding, and improved awareness of asbestos-related risks. As more novel therapies enter clinical trials and regulatory approvals for new drugs expand, the market for mesothelioma treatments is expected to grow. Additionally, greater emphasis on early detection and enhanced diagnostic tools is improving the chances of identifying the disease at a more treatable stage. Growing awareness about the dangers of asbestos exposure, combined with regulatory efforts to limit its use, is also driving attention to mesothelioma, creating opportunities for the development of better preventive measures and treatments.

SCOPE OF STUDY:

The report analyzes the Malignant Mesothelioma market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination, Other Drug Classes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG
• Fresenius Kabi AG
• Merck & Co., Inc.
• Novartis AG
• Ono Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Malignant Mesothelioma - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • Global Economic Update
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Asbestos Exposure Propels Growth in Malignant Mesothelioma Treatments
  • Increased Focus on Early Detection Expands Addressable Market for Diagnostic Tools
  • Technological Advancements in Immunotherapy Strengthen the Business Case for Innovative Treatments
  • Growing Awareness of Occupational Health Risks Spurs Demand for Mesothelioma Screening Programs
  • Emergence of Personalized Medicine Expands Opportunities for Tailored Mesothelioma Therapies
  • Advancements in Targeted Therapies Propel Growth in Precision Oncology for Mesothelioma
  • Increased Research & Development in Novel Drug Candidates Generates New Treatment Opportunities
  • Growing Use of Biomarkers in Early Diagnosis Accelerates Demand for Advanced Diagnostic Solutions
  • Rising Focus on Palliative Care for Mesothelioma Patients Sustains Market Growth for Symptomatic Treatments
  • Expansion of Clinical Trials Strengthens Business Case for Innovative Mesothelioma Treatment Approaches
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Malignant Mesothelioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Malignant Mesothelioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 3: World 15-Year Perspective for Malignant Mesothelioma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
  • TABLE 4: World Malignant Mesothelioma Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Premetrexed & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Premetrexed & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Premetrexed & Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Cisplatin & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Cisplatin & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Cisplatin & Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Carboplatin & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Carboplatin & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Carboplatin & Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Gemcitabine & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Gemcitabine & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Gemcitabine & Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Vinorelbine & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Vinorelbine & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Vinorelbine & Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 23: USA Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: USA 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 26: Canada Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Canada Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: Canada 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
• JAPAN
  • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 29: Japan Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 30: Japan Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: Japan 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
• CHINA
  • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 32: China Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: China Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: China 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
• EUROPE
  • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 35: Europe Recent Past, Current & Future Analysis for Malignant Mesothelioma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: Europe Historic Review for Malignant Mesothelioma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: Europe 15-Year Perspective for Malignant Mesothelioma by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 38: Europe Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Europe Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: Europe 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
• FRANCE
  • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 41: France Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: France Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: France 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
• GERMANY
  • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 44: Germany Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Germany Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Germany 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 47: Italy Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Italy Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Italy 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 50: UK Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: UK Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: UK 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Rest of Europe Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Rest of Europe 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Asia-Pacific Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Asia-Pacific 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030
• REST OF WORLD
  • TABLE 59: Rest of World Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Rest of World Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Rest of World 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2015, 2025 & 2030

IV. COMPETITION